Skye Bioscience Inc (SKYE)
5.53
+0.21
(+3.95%)
USD |
NASDAQ |
Nov 14, 16:00
5.53
0.00 (0.00%)
After-Hours: 20:00
Skye Bioscience Enterprise Value: 93.99M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 93.99M |
| November 12, 2024 | 96.11M |
| November 11, 2024 | 99.45M |
| November 08, 2024 | 105.82M |
| November 07, 2024 | 97.63M |
| November 06, 2024 | 95.50M |
| November 05, 2024 | 94.90M |
| November 04, 2024 | 97.63M |
| November 01, 2024 | 101.27M |
| October 31, 2024 | 91.56M |
| October 30, 2024 | 87.01M |
| October 29, 2024 | 90.95M |
| October 28, 2024 | 88.83M |
| October 25, 2024 | 85.19M |
| October 24, 2024 | 80.64M |
| October 23, 2024 | 90.35M |
| October 22, 2024 | 82.46M |
| October 21, 2024 | 75.48M |
| October 18, 2024 | 73.05M |
| October 17, 2024 | 60.92M |
| October 16, 2024 | 62.44M |
| October 15, 2024 | 60.01M |
| October 14, 2024 | 56.67M |
| October 11, 2024 | 62.74M |
| October 10, 2024 | 46.05M |
| Date | Value |
|---|---|
| October 09, 2024 | 46.05M |
| October 08, 2024 | 50.00M |
| October 07, 2024 | 49.09M |
| October 04, 2024 | 40.29M |
| October 03, 2024 | 41.20M |
| October 02, 2024 | 40.90M |
| October 01, 2024 | 44.54M |
| September 30, 2024 | 51.21M |
| September 27, 2024 | 44.51M |
| September 26, 2024 | 50.88M |
| September 25, 2024 | 48.75M |
| September 24, 2024 | 52.40M |
| September 23, 2024 | 36.62M |
| September 20, 2024 | 26.00M |
| September 19, 2024 | 97.30M |
| September 18, 2024 | 89.71M |
| September 17, 2024 | 90.92M |
| September 16, 2024 | 106.70M |
| September 13, 2024 | 112.77M |
| September 12, 2024 | 112.77M |
| September 11, 2024 | 123.39M |
| September 10, 2024 | 142.80M |
| September 09, 2024 | 123.39M |
| September 06, 2024 | 107.91M |
| September 05, 2024 | 114.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.584M
Minimum
Dec 11 2020
442.02M
Maximum
Mar 28 2024
44.48M
Average
21.20M
Median
Jul 05 2023
Enterprise Value Benchmarks
| Oramed Pharmaceuticals Inc | -58.86M |
| Viking Therapeutics Inc | 5.203B |
| NovaBay Pharmaceuticals Inc | 2.762M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.898M |
| Total Expenses (Quarterly) | 9.522M |
| EPS Diluted (Quarterly) | -0.10 |
| Earnings Yield | -15.15% |
| Normalized Earnings Yield | -8.487 |